key: cord-0837459-o01ztyvh
authors: Dubée, Vincent; Roy, Pierre-Marie; Vielle, Bruno; Parot-Schinkel, Elsa; Blanchet, Odile; Darsonval, Astrid; Lefeuvre, Caroline; Abbara, Chadi; Boucher, Sophie; Devaud, Edouard; Robineau, Olivier; Rispal, Patrick; Guimard, Thomas; d’Anglejean, Emma; Diamantis, Sylvain; Custaud, Marc-Antoine; Pellier, Isabelle; Mercat, Alain
title: Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial
date: 2021-04-01
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.03.005
sha: fd27e6c6598ceaffd98d40737fde4c1160e09429
doc_id: 837459
cord_uid: o01ztyvh

OBJECTIVES: To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild-to-moderate COVID-19 at high risk of worsening. METHODS: We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60 - 74 years and presence of at least one comorbidity. Severely ill patients requiring oxygen therapy > 3L/min or intensive care were excluded. Eligible patients were randomized in a 1:1 ratio to receive either 800mg hydroxychloroquine on Day 0 followed by 400mg per day for 8 days or a placebo. The primary endpoint was a composite of death or start of invasive mechanical ventilation within 14 days following randomization. Secondary endpoints included mortality and clinical evolution at Day 14 and 28, viral shedding at Day 5 and 10. RESULTS: The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 (interquartile range 58 – 86) years and 151/250 (60.4%) patients required oxygen therapy. The primary endpoint occurred in 9/124 (7.3%) patients in the hydroxychloroquine group and 8/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% confidence interval 0.45– 2.80). The rate of positive SARS-CoV-2 RT-PCR at day 5 and 10 was 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary endpoints. CONCLUSION: In this underpowered trial involving mainly older patients with mild-to-moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo.

Men and non-pregnant women aged ≥18 years with a diagnosis of COVID-19 confirmed by positive 121 SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) on a nasopharyngeal swab 122 within 2 days were assessed for eligibility. In centres where RT-PCR could not be performed due to a 123 shortage of swabs or RT-PCR material, the diagnosis could be made based on a chest computed 124 tomography (CT) scan showing typical features of COVID-19. Patients were eligible if they had at 125 least one of the following risk factors for worsening: (i) need for supplemental oxygen to reach a 126 peripheral capillary oxygen saturation of more than 94% (SpO 2 >94%) or a ratio of oxygen partial 127 pressure to fractional inspired oxygen less than or equal to 300 mmHg (PaO 2 /FiO 2 ≤300 mmHg); (ii) 128 age ≥75 years; (iii) age between 60 and 74 years and presence of at least one of the following 129 comorbidities: obesity (body mass index ≥30 kg/m²), arterial hypertension requiring treatment, or 130 diabetes mellitus requiring treatment. 131

Patients requiring more than 3 L/min of oxygen to reach an SpO 2 of 94% were excluded, as were 132 those with a clinical condition necessitating admission to intensive care unit, a negative SARS-CoV-2 133 RT-PCR, a short-term life-threatening comorbidity (life expectancy <3 months), any condition 134 contraindicating hydroxychloroquine treatment (known hypersensitivity or allergy, retinopathy, 135 concomitant treatment associated with a risk of ventricular arrhythmias, use of medications that are 136 contraindicated with hydroxychloroquine and cannot be replaced or stopped during the trial), or 137 conditions associated with an increased risk of adverse event (see Supplementary Appendix for 138 details). Of note, concomitant treatment with azithromycin was allowed. 139

For patients with an initial positive SARS-CoV-2 RT-PCR, nasopharyngeal swabs were sampled on Day 141 5 and 10 after randomization, and SARS-CoV-2 RT-PCR was performed using the same local 142 technique as the initial All adverse events that occurred during a patient's participation were declared to the sponsor, with 144 the exception of adverse events linked to the COVID-19 itself (for details, see the protocol, available 145 in the Supplementary Materials). 146 J o u r n a l P r e -p r o o f Outcome measures 147

The primary endpoint was a composite of death and the need for invasive mechanical ventilation 148 within 14 days following randomization. Secondary efficacy outcomes included the rate of mortality 149 or invasive ventilation within 28 days following treatment initiation, clinical evolution using the 150 recovery (score of 0, 1, or 2 on the ordinal scale). The secondary safety outcome consisted in the 157 rate of serious adverse events at Day 28. Clinical events were adjudicated by an independent event 158 adjudication committee, whose members were unaware of group assignments. 159

The protocol was approved by an independent protection committee and by the French National 161

Agency for Medicines and Health Products Safety (ANSM), according to French regulations. Written 162 informed consent was obtained prior to any study procedure from each patient or from the patient's 163 legal representative if the patient was unable to provide consent. 164

Based on the first available epidemiological data on 14] , we estimated the rate of the 166 primary outcome to be 20%. A headcount of 615 patients per group allows demonstrating, under a 167 bilateral hypothesis, an absolute difference of 6% between the two groups (relative difference of 168 30%), with an alpha risk of 5% and a power of 80%. To allow for up to 5% non-evaluable or lost-to-169 follow-up patients, we set the sample size at 1,300 patients in total. 170 J o u r n a l P r e -p r o o f Our main analysis was performed in the intention-to-treat population. Interim analyses were 171 performed by conducting the triangle test on every 50 patients and were submitted to the 172 Independent Data and Safety Monitoring Board that was formed for this study. A sensitivity analysis 173 was performed in the per-protocol population, i.e., patients with no major deviation from the study 174 protocol. For the safety analysis, all patients who received at least one dose of hydroxychloroquine 175 were included in the intervention group. 176

The rates of the primary outcome were compared between the two groups using the Chi-squared 177 test. The relative risks for each clinical event at Day 14 and 28 and their 95% confidence interval (CI) 178

were calculated with an adjustment taking into account the baseline status using a Mantel-Haenszel 179

A sequential analysis based on the triangle test was performed using R software, version 3.6.3. Stata 181 software (version 13) was used for other analyses. 

Patients 187

The trial started on April 1, 2020 and was suspended on May 26, 2020 by the French regulatory 188 authority because of reports of hydroxychloroquine toxicity in pharmacovigilance databases [15] and 189 observational studies [16] . It was definitively stopped by the sponsor on June 9, 2020 because of a 190 low inclusion rate in the context of the slowdown of the pandemic in France ( Figure S1 ). 191

In the 33 centers that completed the screening survey, 11% (202 patients out of 1,822 patients) of 192 the patients assessed for eligibility were included in the study. In total, 250 patients were 193 randomized, of which 125 were assigned to receive hydroxychloroquine and 125 the placebo ( Figure  194 1). Among them, one and two patients withdrew consent in the hydroxychloroquine and placebo 195 groups, respectively. The per-protocol population comprised 226 patients: 116 in the placebo group 196 and 110 in the hydroxychloroquine group. A summary of the major violations that led to exclusion 197 from the per-protocol population is provided in the Supplementary appendix. 198

The median age was 77 (interquartile range [IQR]: 58-86) years ( Figure S2 ), and 60% of the patients 199 required supplemental oxygen at baseline ( Table 1 ). The median time from symptom onset to 200 randomization was 5 days (IQR: 3-9). The treatment groups were well balanced for baseline 201 demographic and clinical characteristics, as well as for the treatments of interest received at 202 randomization. 203

There was no significant difference in the rate of the primary endpoint, which occurred within 205 14 days following randomization in 8 of 123 patients assigned to the placebo group (6.5%) and 9 of 206 124 patients assigned to the hydroxychloroquine group (7.3%) (relative risk 1.12; 95% CI: 0.45 to 207 2.80; P=0.82) (Table 2 and Figure S3 ). At 28 days after randomization, 9.8% (12/123) of the patients 208 in the placebo group had died or had been intubated compared to 7.3% (9/124) in the 209 hydroxychloroquine group (relative risk 0.74; 95% CI: 0.33 to 1.70; Table 2 ). Details about the cause 210 of death can be found in the supplementary material (Table S3) . 211

In the per-protocol population, death or requirement for invasive mechanical ventilation within 14 212 days was observed in 6 of the 116 patients (5.2%) who received the placebo and in 7 of the 110 213 patients treated with hydroxychloroquine (6.4%). The relative risk for death or invasive mechanical 214 ventilation was 1.23 (95% CI: 0.43-3.55) (Table S2) Table 2 ). The rate of SARS-CoV-2-positive RT-PCR did not differ significantly between 228 the two groups. 229

Analysis of the different outcomes in predefined subgroups can be found in the Supplementary 230 material ( Figure S4 ). 231

Adverse events occurred in 70 of the 124 patients treated with hydroxychloroquine (56.5%) 233 compared to 61 of the 120 patients who received the placebo (50.8%) ( In this trial involving patients with mild-to-moderate COVID-19 at higher risk of worsening, we did 239 not observe a significant difference in the rate of death or start of mechanical ventilation at 14 days 240 following inclusion between patients treated with hydroxychloroquine and those who received the 241 placebo. The rate of serious adverse events was also similar in the two groups. The lack of power is the main limitation of our trial. The study was prematurely stopped after the 258 inclusion of 19% of the planned number of patients due to the slowdown of the epidemic and 259

following the publication of a subsequently retracted study raising concerns over 260 hydroxychloroquine cardiovascular toxicity [16] . Severe cardiovascular adverse events with 261 hydroxychloroquine were also reported by the French Network of Pharmacovigilance Centers [15] . 262

Finally, an open labelled and a retrospective studies provided negative results on the clinical efficacy 263 of hydroxychloroquine in mild-to-moderate COVID-19 patients [5, 7] . All have contributed to an 264 important decrease of inclusions, questioning study feasibility and justifying an early termination of 265 the trial. Indeed, the daily number of new covid-19 cases had dramatically decreased in France 266 ( Figure S1 ) and lead to consider impossible to achieve the planned number of inclusions. 267

We did not identify any safety concerns related to hydroxychloroquine use. However, we excluded 268 patients with conditions that put them at risk of increased hydroxychloroquine toxicity, such as 269 hypokalemia, prolonged corrected QT interval, or concomitant treatment with an increased risk of 

J o u r n a l P r e -p r o o f 

Service de médecine interne et maladies infectieuses

Service de maladies infectieuses et tropicales

Other people who contributed to the study but do not fulfill the criteria for auhtorship Center First Name